Sub-Total: $0.00 USD
Endocrine Disruptor Testing
Functional Assessment of Hormone and Receptor-Mediated Safety Risk
Unintended modulation of hormone signaling pathways remains a significant source of late-stage failure and regulatory concern across pharmaceutical, chemical, and environmental safety programs. Endocrine disruptor testing is critical for identifying compounds that interfere with nuclear receptors or endocrine-regulated pathways, where adverse effects can occur even at low exposures and may be missed by simplified or non-functional screening approaches.
INDIGO Biosciences’ Endocrine Disruptor Testing and Functional Endocrine Profiling services provide human-relevant, cell-based assessment of endocrine and receptor-mediated activity, enabling early identification of hormone disruption, receptor cross-reactivity, and off-target signaling before these liabilities progress downstream.
Human-Relevant Endocrine Disruptor Testing Services
INDIGO offers comprehensive panels of cell-based, functional nuclear receptor assays designed to evaluate endocrine and receptor-mediated activity across key human signaling pathways.
Our assays focus on functional receptor activation or inhibition, rather than binding alone, providing biologically meaningful insight into how compounds modulate hormone-regulated pathways in intact cellular systems.
Assays are available in agonist, antagonist, or mixed-mode formats and can be configured as focused endocrine disruptor screening or broader profiling panels depending on program needs.
Key receptor pathways assessed include:
- Estrogen receptors (ERα and ERβ)
- Androgen receptor (AR)
- Thyroid hormone receptors (TRα and TRβ)
- Metabolic and lipid homeostasis pathways (e.g., PPARs, LXRs, FXR)
- Additional nuclear receptors and stress-response pathways, as needed
Endocrine Disruptor Testing Across Key Hormone Signaling Pathways
INDIGO’s endocrine disruptor testing studies are designed to integrate seamlessly into discovery and safety workflows, with flexibility to match compound class, regulatory context, and development stage.
Available options include:
- Concentration–response testing for potency and ranking
- Agonist, antagonist, or dual-mode assessment
- Focused receptor panels or expanded profiling
- Comparative testing across compound series
- Integration with metabolism, liver safety, or off-target panels
This flexibility supports both early endocrine hazard identification and more detailed follow-up investigations when endocrine disruption risk is suspected.
Endocrine Disruptor Testing Data Supports Confident Decisions
Data generated from INDIGO’s endocrine disruptor testing assays are designed to be interpretable and actionable, rather than purely descriptive. Clients use the results to:
- Rank compounds based on relative receptor activity
- Identify off-target or unintended endocrine effects
- Guide structure–activity relationship (SAR) optimization
- Inform integrated safety assessments alongside liver or DDI data
- Support internal go/no-go decisions with mechanistic context
Outputs typically include concentration–response curves, potency values, and receptor-specific activity profiles suitable for internal reporting or regulatory-facing documentation.
Common Applications of Endocrine Disruptor Testing
INDIGO’s Endocrine Disruptor Testing services are commonly used to:
- Screen compounds for endocrine disruption potential
- Identify receptor-mediated safety liabilities during lead optimization
- Support chemical safety and regulatory decision making
- De-risk programs prior to in vivo studies
- Provide human-relevant data for NAM-based safety strategies
- Provide methods to assess metabolite activity
Early identification of endocrine activity enables teams to refine chemistry, adjust exposure strategies, or deprioritize compounds before costly downstream investment.
Why Endocrine Disruptor Testing Requires Functional, Human-Relevant Models
Endocrine disruption often arises from subtle or context-dependent receptor modulation that may not be detected in binding assays or narrowly focused reporter systems. In addition, species differences, receptor cross-talk, and metabolism-dependent formation of active or toxic metabolites can further complicate interpretation, underscoring the importance of assessing both parent compounds and their metabolites in human-relevant systems.
By focusing on functional outcomes, these assays provide clearer insight into potential endocrine risk earlier in development.
INDIGO’s functional endocrine profiling approach allows you to:
- Detect biologically relevant receptor activation or inhibition
- Identify partial agonism or mixed-mode activity
- Reveal off-target receptor effects beyond the intended mechanism
- Evaluate metabolism-dependent effects on endocrine receptor modulation
- Generate data aligned with human-relevant NAM strategies and AOP driven risk assessment
Request Endocrine Disruptor Testing
Start a conversation with our scientists to define the right study for your program.
Submit Your Compound and Study Goals
Share basic information about your compound, development stage, and safety questions. This allows our team to recommend an appropriate endocrine screening strategy.
Review a Customized Study Proposal
You’ll receive a tailored study outline with recommended assays, timelines, and pricing designed to address endocrine safety risk relevant to your program.
Move Forward with Scientific Support
Once approved, INDIGO scientists coordinate study execution and remain available to discuss results, interpret findings, and plan next steps as needed.
